Subgroup analyses based on various clinical factors—including age, PD‐1 expression status, HER2 expression status, prior treatment with or without taxanes, tumor heterogeneity, presence of visceral metastasis, treatment stage (initial diagnosis as stage IV, disease‐free survival (DFS) ≤ 12 months, DFS > 12 months), and current treatment lines—consistently demonstrated a superior benefit of chemotherapy combined with anti‐PD‐1 mAb over chemotherapy combined with bevacizumab in terms of PFS (Figure 3). The gene discussed is ERBB2; the disease is neoplasm.